ChartRow logo
NTRA
Natera Inc.Stock · Health Care
$265.38−$9.24 (-3.36%)as of market close, Aug 6, 2026
CompareLLYUNHJNJABBVISRGTMO

NTRA financial statements

The full income statement, balance sheet, and cash-flow statement for Natera Inc. (NTRA), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.

Shares outstanding (point-in-time)

2024-03 122.8M2024-06 123.7M2024-09 132.0M2024-12 135.2M2025-03 136.5M2025-06 137.2M2025-09 138.0M2025-12 141.7M2026-03 143.2M+16.6% over 8 periods

SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.

As-reported fiscal years.
Line itemTrendFY2025FY2024FY2023FY2022FY2021
Income Statementas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Revenue
2.31B
YoY+35.9%
1.70B
YoY+56.7%
1.08B
YoY+32.0%
820M
YoY+31.1%
625M
YoY+60.0%
Research & development
624M
YoY+54.4%
404M
YoY+26.0%
321M
YoY+1.3%
316M
YoY+19.8%
264M
YoY+164.1%
Selling, general & administrative
1.18B
YoY+39.9%
841M
YoY+36.1%
618M
YoY+5.0%
589M
YoY+15.2%
511M
YoY+68.3%
Restructuring
400K
Amortization of intangibles
3.90M
YoY+290.0%
1.00M
0.00
Provision for credit losses
1.61M
YoY+25.6%
1.28M
YoY-51.6%
2.65M
YoY+49.4%
1.77M
YoY+1034.6%
156K
YoY-88.5%
Operating income
-310M
YoY-39.4%
-222M
YoY+50.2%
-446M
YoY+17.5%
-541M
YoY-15.6%
-468M
YoY-116.5%
Interest expense
4.07M
YoY-61.9%
10.7M
YoY-15.5%
12.6M
YoY+35.6%
9.32M
YoY+12.2%
8.30M
YoY-44.9%
Gain (loss) on equity securities
2.00K
YoY-81.8%
11.0K
Pre-tax income
-268M
YoY-41.3%
-190M
YoY+56.3%
-435M
YoY+20.5%
-547M
YoY-16.1%
-471M
YoY-105.1%
Income tax
-59.9M
YoY-8722.9%
695K
YoY+156.5%
271K
YoY-72.3%
978K
YoY+58.3%
618K
YoY+530.6%
-208M
YoY-9.3%
-190M
YoY+56.2%
-435M
YoY+20.6%
-548M
YoY-16.1%
-472M
YoY-105.3%
-$1.52
YoY+0.7%
-$1.53
YoY+59.5%
-$3.78
YoY+32.1%
-$5.57
YoY-6.9%
-$5.21
YoY-83.5%
Balance Sheetas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
1.50B
YoY+8.8%
1.38B
YoY+9.3%
1.26B
YoY+3.9%
1.21B
YoY+10.9%
1.09B
YoY+26.7%
2.40B
YoY+44.4%
1.66B
YoY+15.2%
1.44B
YoY+3.4%
1.39B
YoY+12.8%
1.24B
YoY+32.6%
441M
YoY+28.2%
344M
YoY+12.0%
307M
YoY-1.0%
310M
YoY+41.8%
219M
YoY+10.0%
686M
YoY+47.4%
465M
YoY-31.2%
676M
YoY-1.8%
689M
YoY+18.1%
583M
YoY+30.8%
1.71B
YoY+43.2%
1.20B
YoY+56.2%
765M
YoY+8.4%
706M
YoY+8.0%
653M
YoY+34.4%
Cash Flowas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
215M
YoY+58.7%
136M
YoY+154.9%
-247M
YoY+42.8%
-432M
YoY-28.7%
-335M
YoY-83.7%
-132M
YoY-196.1%
138M
YoY-18.3%
168M
YoY-49.0%
330M
YoY+261.0%
-205M
YoY+38.1%
47.5M
YoY+57.1%
30.2M
YoY-88.1%
254M
YoY-47.3%
483M
YoY-16.2%
576M
YoY+15.0%
Interest paid
4.07M
YoY-48.5%
7.90M
YoY-30.4%
11.3M
YoY+40.8%
8.06M
YoY+13.9%
7.08M
YoY+114.7%
Income taxes paid
499K
YoY-61.8%
1.31M
YoY+343.1%
295K
YoY-46.3%
549K
YoY+94.0%
283K
YoY+322.4%
Valuation Ratiosas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Market cap
32.5B
YoY+51.7%
21.4B
YoY+184.3%
7.53B
YoY+92.0%
3.92B
YoY-56.0%
8.92B
YoY+3.5%
P/S
14.1×
YoY+11.6%
12.6×
YoY+65.7%
7.6×
YoY+50.7%
5.1×
YoY-64.6%
14.3×
YoY-35.3%
P/B
19.0×
YoY+5.9%
17.9×
YoY+86.6%
9.6×
YoY-11.5%
10.8×
YoY-20.6%
13.6×
YoY-23.0%
P/FCF
297.6×
YoY-3.7%
309.1×
0.34%
YoY+3.9%
0.32%
Source filing10-K10-K10-K10-K10-K

About this data

Source: NTRA's SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn't file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all NTRA filings on SEC EDGAR → Not investment advice.